IL6 and prostate carcinoma: The study conducted by Christensen et al. on a cohort of 42 patients with prostate cancer treated with IMRT [30] demonstrated a significant rise in serum levels of IFN-γ and IL-6 during radiotherapy in prostate cancer patients.